- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Daily oral orforglipron leads to significant weight loss in obese/overweight people: NEJM
![Daily oral orforglipron leads to significant weight loss in obese/overweight people: NEJM Daily oral orforglipron leads to significant weight loss in obese/overweight people: NEJM](https://medicaldialogues.in/h-upload/2023/06/29/750x450_213097-weight-loss-2.webp)
USA: Daily oral orforglipron led to weight loss in adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes, reported a recent study published in The New England Journal of Medicine.
Adverse events seen with orforglipron, a nonpeptide GLP-1 receptor agonist, were similar to those with injectable GLP-1 receptor agonists.
Obesity is a global health problem and is a risk factor for many leading causes of illness and death. There is a need for data regarding the safety and efficacy of orforglipron, a nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, as a once-daily oral therapy for weight reduction in obese adults in phase 2, randomized, double-masked trial.
The trial enrolled adults with overweight or obesity plus at least one weight-related coexisting condition without diabetes. Two hundred seventy-two participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. At week 26 (primary endpoint), the authors assessed the percentage change from baseline in body weight and at week 36 (secondary endpoint). At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9.
The study revealed the following findings:
- At week 26, the mean change from baseline in body weight ranged from −8.6% to −12.6% across the orforglipron dose cohorts and was −2.0% in the placebo group.
- At week 36, the mean change ranged from −9.4% to −14.7% with orforglipron and was −2.3% with placebo.
- A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, compared with 9% who received a placebo.
- The use of orforglipron improved all prespecified weight-related and cardiometabolic measures.
- The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts.
- The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class.
Currently approved GLP-1 agonists for type 2 diabetes and/or obesity are peptide-based and given orally or by subcutaneous injection. No oral GLP-1 agonists are approved for obesity, and only oral semaglutide is approved for type 2 diabetes, the authors noted.
The formulation of oral semaglutide is done with an ingredient that helps protects its degradation and enhances gastric absorption. To maximize efficacy and absorption, the doctors advise taking it in the fasting stage and not drinking or eating anything for at least 30 minutes after. The bioavailability of orally ingested semaglutide is only 1% or less.
"In contrast, Orforglipron is a small molecule that isn't a peptide, so it isn't degraded in the gastrointestinal tract and can be taken with or without food," Manige Konig, Eli Lilly, Indianapolis, IN, and colleagues concluded.
Reference:
The study, "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity," was published in The New England Journal of Medicine.
DOI: 10.1056/NEJMoa2302392
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751